Prevalence and outcomes of <scp>DKA</scp> in type 1 and type 2 <scp>DM</scp> patients treated and not treated with <scp>SGLT</scp> ‐2 inhibitors

Pre-hospital SGLT2 inhibitor therapy in patients presenting with DKA was associated with substantially lower long-term mortality and no increase in short-term mortality or readmissions, supporting the safety of these agents when appropriate monitoring is in place. Pre-hospital SGLT2 inhibitor therapy in patients presenting with DKA was associated with improved long-term survival and no increase in short-term mortality, supporting their continued use with appropriate clinical monitoring.